Abstract

Background: Diabetes is considered as a cardiovascular event. In patients with diabetes, being overweight or obese increases the risk of cardiovascular events. Objectives: 1) Describe clinical and subclinical characteristics in type 2 diabetes patients with overweight and obesity; 2) Evaluation of the effectiveness of treatment with SGLT2i in combination with metformin and some related factors in type 2 diabetes patients with overweight and obesity. Materials and methods: A cross-sectional descriptive study with analysis was conducted on 80 overweight and obese type 2 diabetes patients who came for examination and treatment at the Endocrinology clinic, Hoan My Cuu Long General Hospital from January to September 2022. Results: 52,5% of the study population is male, the average age was 58,2 years old, the proportion of patients with diabetes duration >5 years accounted for 71,2%. After 6 months of treatment: BMI, waist circumference, fasting plasma glucose, HbA1c improved statistically, p<0,05. When analyzing the relationship, the difference was statistically significant between male and female sex in weight control, OR=3,5 95% CI; The difference between 2 drugs (Empagliflozin and Dapagliflozin) in controlling male waist circumference was statistically significant, OR=8,18 95% CI. Conclusion: SGLT2i combined with metformin in overweight and obese type 2 diabetes patients helped control weight, male waist circumference, fasting plasma glucose and HbA1c.